Rivaroxaban versus low-molecular-weight heparin and fondaparinux for preventing deep vein thrombosis after total knee arthroplasty in high-altitude residents: a randomized controlled trial Authors: Liangjuan Ren, Hongxia Fang, Xiaoqin Fu, Xin Chu, Xinjun Liu, Lihan Shi, Pai Zheng Published: 2026 ABSTRACT BackgroundHigh-altitude residence (defined as ≥ 1500 m above sea level) is associated with chronic hypoxia and increased thrombotic risk. This study aimed to evaluate the comparative efficacy and safety of rivaroxaban, low-molecular-weight heparin (LMWH), and fondaparinux for preventing deep vein thrombosis (DVT) after total knee arthroplasty (TKA) in long-term high-altitude residents.MethodsIn this randomized controlled trial, 90 high-altitude residents undergoing primary TKA were randomly assigned to one of three groups: rivaroxaban (group A), LMWH (group B), or fondaparinux (group C). The primary outcome was the incidence of postoperative DVT assessed by duplex ultrasonography on postoperative day 14. Secondary outcomes included coagulation indicators (PT, APTT, FIB, PLT, D-dimer), inflammatory markers (CRP, PCT, IL-6, ESR, WBC), knee circumference, intraoperative blood loss, and bleeding-related adverse events.ResultsDVT incidence was 0% in the rivaroxaban group, compared with 16.7% in the LMWH group and 13.3% in the fondaparinux group (P = 0.016). On postoperative day 14, D-dimer levels were significantly lower in the rivaroxaban group than in LMWH (P < 0.001) and fondaparinux (P < 0.001) and lower in fondaparinux than LMWH (P < 0.001). PT and APTT were higher in the rivaroxaban group compared with LMWH (PT P < 0.001, APTT P = 0.012) and fondaparinux (PT P < 0.001, APTT P = 0.035). FIB and PLT showed no significant differences. CRP and PCT were significantly lower with rivaroxaban than LMWH (CRP P < 0.001, PCT P < 0.001) and fondaparinux (CRP P = 0.018, PCT P = 0.018), while IL-6, ESR, and WBC showed no group differences. Intraoperative blood loss and bleeding complications were comparable across groups.ConclusionAmong high-altitude residents undergoing TKA, rivaroxaban demonstrated superior efficacy in preventing postoperative DVT and reducing inflammatory response without increasing bleeding risk. These findings contribute important evidence to guide anticoagulant selection in populations living at high altitude, who face unique thrombotic challenges due to chronic hypoxia.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13063-025-09371-y. Introduction High altitude is defined as an altitude of 1500 m or more, where between 1500–3500 m is high altitude, 3500–5500 m is ultrahigh altitude, and 5500 m or more is very high altitude. Cancienne et al.’s study showed that high altitude is an important risk factor for postoperative VTE, and the risk of VTE in comparison to residents of lower altitudes is 30 to 44 times greater [1]. This may be due to the fact that in patients who have lived at high altitude for a long period of time (1 year or more), the low-pressure hypoxia stimulates the production of erythropoietin in the kidneys and liver, which stimulates the production of erythrocytes, increasing their concentration and size and inducing hypercoagulability of the blood [2]. This leads to an increase in factor VIII-mediated thrombin production and has an effect on platelet function and fibrinogen levels, thereby increasing the risk of venous thrombosis [3]. In surgical patients at high altitude, the postoperative hypercoagulable state of the blood is exacerbated, leading to microcirculatory disorders and even VTE, which in turn exacerbate tissue hypoxia, creating a vicious cycle that ultimately leads to organ damage [4–6]. Given this high-thrombosis-risk environment, effective prophylaxis against lower extremity deep vein thrombosis is of particular importance for high-altitude patients undergoing total knee arthroplasty (TKA). Conventional anticoagulant options include heparin, low-molecular-weight heparin (LMWH), rivaroxaban, and fondaparinux. Heparin and LMWH exert anticoagulant effects via antithrombin-mediated inhibition of coagulation factors, whereas fondaparinux and rivaroxaban target factor Xa. However, the pathophysiological features of high-altitude patients—namely increased hematocrit, high plasma viscosity, and enhanced platelet activation—raise mechanistic considerations regarding the relative efficacy of these anticoagulants. In such hypercoagulable states, direct factor Xa inhibitors like rivaroxaban may theoretically offer advantages by inhibiting both free and prothrombinase-bound factor Xa independently of antithrombin, potentially providing more consistent suppression of thrombin generation under hypoxic conditions. Despite this, few studies have evaluated whether these mechanistic differences translate into clinical benefit in high-altitude TKA patients. Our medical center in Chengdu, Sichuan province, receives a large number of referrals from high-altitude regions of the Tibetan Plateau due to limited local medical resources. This provides an opportunity to evaluate thromboprophylaxis strategies in a well-defined high-altitude TKA population. Therefore, we conducted a randomized controlled trial to compare the postoperative effectiveness and safety of rivaroxaban, LMWH, and fondaparinux sodium in patients living at high altitude (≥ 1500 m) undergoing primary TKA. The primary outcome was the incidence of postoperative DVT within 14 days, with secondary evaluations including coagulation indicators, inflammatory markers, and bleeding-related complications. We hypothesized that rivaroxaban would demonstrate superior prophylactic efficacy while maintaining a comparable safety profile relative to LMWH and fondaparinux sodium in this high-risk population. Materials and methods The study was registered in ClinicalTrials.gov and approved by the ethics committee of our hospital, all patients signed an informed consent form, and the whole experiment was conducted in the Department of Orthopaedic Surgery of our hospital. Patient recruitment Patients with a diagnosis of osteoarthritis of the knee and a history of prolonged residence in the highlands who were scheduled for TKA surgery were selected. Patients were excluded if they had a history of venous thromboembolism (VTE); coagulation abnormalities or peripheral vascular complications; prolonged use of anticoagulant and antiplatelet medications to treat disease; severe hepatic or renal injury; comorbidities such as cancer and diseases of the heart, brain, liver, and other vital organs; and a history of invasive procedures within the previous 3 months (dental extractions, surgeries, etc.). We also excluded patients who were allergic to rivaroxaban, sodium low molecular heparin, and sodium sulfadoxine heparin. Patient demographic and preoperative characteristics were recorded preoperatively. Randomization and medication Eligible subjects were divided into three groups using a table of random numbers, and a computer-generated sequence of random assignments was concealed in sequentially numbered sealed envelopes by a statistician not involved in data analysis. A nurse not involved in patient management pre-prepared the study drug or placebo according to the group assignment. For patients in group A, oral rivaroxaban (Bayer AG, 10 mg) was started at a daily dose of 10 mg from the second day of admission and discontinued until 12 h before surgery. Oral administration was started again 12 h after completion of surgery until discharge. For patients in group B, low-molecular-weight heparin natriuretic sodium (Sanofi, 4000 AXaIU) was administered subcutaneously in the abdominal wall at a dose of 0.4 mL 12 h before surgery. A daily subcutaneous injection into the abdominal wall at a dose of 0.4 mL was administered 12 h after completion of surgery and continued until discharge. For patients in group C, a subcutaneous injection of fondaparinux (Aspen, 2.5 mg) into the abdominal wall at a dose of 2.5 mg once daily was administered 12 h after completion of the procedure and continued until discharge from the hospital. Surgical technique and perioperative management All patients were operated on by a single senior surgeon with appropriate antibiotics to prevent infection for 1 h prior to skin removal. Intraoperative temperature was maintained by means of thermal blankets, fluids, and anesthetic gases. Intraoperative bleeding was controlled by intravenous infusion of tranexamic acid and local injection into the joint cavity. Local injection of “cocktail” analgesic was given to reduce early postoperative pain. The operations were performed by median incision of the knee joint and medial parapatellar approach, and tourniquets and drainage tubes were routinely applied. The brand of prosthesis was selected by the patient after consultation with the attending surgeon, and all of them were posterior-stabilized fixed-platform prostheses with bone cement fixation, without patella replacement. The application of pneumatic compression devices and graduated compression stockings to promote venous return was started immediately after surgery. A pneumatic compression device (Kinetic-Air™ IPC System, Xiangyu Medical, China) was used in an intermittent sequential compression mode with a pressure range of 40–60 mmHg, cycling every 60 s, and applied for at least 12 h per day during the first three postoperative days, as tolerated. Postoperative analgesia was provided through a combination of physical therapy and analgesic medications. Physiotherapy mainly included elevation of the affected limb, application of ice packs, and nonthermal low-intensity visible red LED light therapy (photobiomodulation) for local wound care. The choice of analgesic drugs was based on the patient’s VAS score: nonsteroidal anti-inflammatory drugs for scores of 0–3, non-opioids or weak opioids for scores of 4–6, and non-opioids or strong opioids for scores of 7–9. Wound drains were removed 24–48 h after surgery depending on drainage volume, and urinary catheters were removed within 12 h postoperatively. Outcome measures The primary outcome was the incidence of postoperative DVT assessed by duplex ultrasonography on postoperative day 14. Secondary outcomes included coagulation indicators (PT, APTT, FIB, PLT, D-dimer), inflammatory markers (CRP, PCT, IL-6, ESR, WBC), knee circumference, intraoperative blood loss, and bleeding-related adverse events. Statistical analysis The sample size was mainly based on D-dimer levels at 14 days postoperatively in the three groups, which according to the pre-test we observed to be 2.28 ± 0.43 in group A, 2.67 ± 0.30 in group B, and 2.64 ± 0.07 in group C. Using PASS 11.0 software (NCSS, LLC, Kaysville, UT, USA), taking α = 0.05 and power = 0.9, it was calculated that a minimum of 27 subjects were needed in each group. Assuming a 10% shedding rate, a minimum of 30 participants were needed in each group, totaling 90. Statistical analysis was performed using SPSS 26.0 software (IBM, USA). Measurement data that conformed to normality were analyzed using mean and standard deviation for descriptive statistics, one-way ANOVA for overall comparison between groups, and the Bonferroni method for two-way comparison; for skewed data, median and pre- and post-quartiles were used for descriptive analysis, and the rank-sum test was used for between-group comparisons. Count data were expressed as numbers and percentages and analyzed statistically using the cross-tabular chi-square test. p < 0.05 was considered a statistically significant difference. Results Patients Between April 2022 and December 2023, 93 patients with a history of high-altitude residence scheduled for TKA surgery were screened. Of these, one patient did not consent to participate in this trial, and two were excluded because of a history of previous deep vein thrombosis. A total of 90 eligible patients remained. These patients were randomized into three groups (group A, group B, and group C) of 30 patients each. There was no statistically significant difference in baseline characteristics between the three groups (Table 1). Table 1Baseline characteristics of the patients according to study groupVariableGroup A (N = 30)Group B (N = 30)Group C (N = 30)Statisticsp-value (95% CI)IIIIIIIVAge (years)70.73 ± 5.4369.17 ± 6.1771.73 ± 5.841.4810.2330.300 (−1.42 to 4.550.508 (−3.99 to 1.98)0.91 (−5.56 to 0.42Sex (male/female)16/1418/1213/171.6920.429---BMI (kg/m2)25.05 ± 4.3625.96 ± 3.0825.80 ± 4.010.4800.6200.361 (−2.89 to 1.07)0.451 (−2.73 to 1.23)0.873 (−1.82 to 2.14)Knee circumference (cm)40.96 ± 3.2941.66 ± 3.08411.36 ± 3.710.3230.7250.429 (−2.43to 1.03)0.650 (−2.13 to 1.33)0.731 (−2.03 to 1.43)Preoperative values Hb (g/L)145.83 ± 24.32149.53 ± 19.69147.17 ± 20.830.2240.8000.511 (−14.84 to 7.44)0.812 (−12.47 to 9.80)0.674 (−8.77 to 13.50) ESR (mm/h)17.03 ± 4.2116.03 ± 5.4117.10 ± 5.540.4140.6620.448 (−1.61 to 3.61)0.960 (−2.68 to 2.54)0.419 (−3.68 to 1.54) CRP (mg/L)6.42 ± 5.035.94 ± 5.646.15 ± 6.100.0540.9470.744 (−2.40 to 3.35)0.854 (−2.61 to 3.14)0.887 (−3.08 to 2.67) IL-6 (pg/L)9.20 ± 1.278.92 ± 1.309.01 ± 1.500.3330.7180.427 (−0.42 to 0.98)0.586 (−0.51 to 0.89)0.801 (−0.79 to 0.61) WBC (109/L)8.01 ± 2.458.31 ± 2.188.09 ± 2.052.2080.1160.129 (−0.07 to 0.81)0.487 (−0.18 to 0.69)1.000 (−0.55 to 0.32) PCT (ng/mL)1.37 ± 0.301.26 ± 0.241.34 ± 0.291.3180.2730.127 (−0.03 to 0.25)0.745 (−0.12 to 0.17)0.228 (−0.23 to 0.06) APTT (s)37.17 ± 3.9836.31 ± 3.1436.54 ± 3.130.5040.6060.335 (−0.91 to 2.62)0.126 (−0.07 to 2.40)0.799 (−1.99 to 1.54) PT (s)12.45 ± 0.7011.95 ± 1.1212.08 ± 0.712.7150.0720.083 (−0.04 to 1.04)0.294 (−0.17 to 0.92)1.000 (−0.67 to 0.42) FIB (g/L)3.75 ± 0.593.86 ± 0.583.84 ± 0.590.2730.7620.499 (−0.41 to 0.20)0.556 (−0.39 to 0.21)0.930 (−0.29 to 0.32) PLT (109/L)216.63 ± 70.07210.33 ± 53.33215.60 ± 53.760.0970.9080.683 (−24.27 to 36.87)0.947 (−29.54 to 31.60)0.733 (−35.84 to 25.30) D-Dimer (mg/L)1.43 ± 0.671.52 ± 0.801.56 ± 0.850.2010.8180.666 (−0.48 to 0.31)0.539 (−0.52 to 0.27)0.854 (−0.44 to 0.36)I, A vs B vs C; II, A vs B; III, A vs C; IV, B vs C Table 1Baseline characteristics of the patients according to study groupVariableGroup A (N = 30)Group B (N = 30)Group C (N = 30)Statisticsp-value (95% CI)IIIIIIIVAge (years)70.73 ± 5.4369.17 ± 6.1771.73 ± 5.841.4810.2330.300 (−1.42 to 4.550.508 (−3.99 to 1.98)0.91 (−5.56 to 0.42Sex (male/female)16/1418/1213/171.6920.429---BMI (kg/m2)25.05 ± 4.3625.96 ± 3.0825.80 ± 4.010.4800.6200.361 (−2.89 to 1.07)0.451 (−2.73 to 1.23)0.873 (−1.82 to 2.14)Knee circumference (cm)40.96 ± 3.2941.66 ± 3.08411.36 ± 3.710.3230.7250.429 (−2.43to 1.03)0.650 (−2.13 to 1.33)0.731 (−2.03 to 1.43)Preoperative values Hb (g/L)145.83 ± 24.32149.53 ± 19.69147.17 ± 20.830.2240.8000.511 (−14.84 to 7.44)0.812 (−12.47 to 9.80)0.674 (−8.77 to 13.50) ESR (mm/h)17.03 ± 4.2116.03 ± 5.4117.10 ± 5.540.4140.6620.448 (−1.61 to 3.61)0.960 (−2.68 to 2.54)0.419 (−3.68 to 1.54) CRP (mg/L)6.42 ± 5.035.94 ± 5.646.15 ± 6.100.0540.9470.744 (−2.40 to 3.35)0.854 (−2.61 to 3.14)0.887 (−3.08 to 2.67) IL-6 (pg/L)9.20 ± 1.278.92 ± 1.309.01 ± 1.500.3330.7180.427 (−0.42 to 0.98)0.586 (−0.51 to 0.89)0.801 (−0.79 to 0.61) WBC (109/L)8.01 ± 2.458.31 ± 2.188.09 ± 2.052.2080.1160.129 (−0.07 to 0.81)0.487 (−0.18 to 0.69)1.000 (−0.55 to 0.32) PCT (ng/mL)1.37 ± 0.301.26 ± 0.241.34 ± 0.291.3180.2730.127 (−0.03 to 0.25)0.745 (−0.12 to 0.17)0.228 (−0.23 to 0.06) APTT (s)37.17 ± 3.9836.31 ± 3.1436.54 ± 3.130.5040.6060.335 (−0.91 to 2.62)0.126 (−0.07 to 2.40)0.799 (−1.99 to 1.54) PT (s)12.45 ± 0.7011.95 ± 1.1212.08 ± 0.712.7150.0720.083 (−0.04 to 1.04)0.294 (−0.17 to 0.92)1.000 (−0.67 to 0.42) FIB (g/L)3.75 ± 0.593.86 ± 0.583.84 ± 0.590.2730.7620.499 (−0.41 to 0.20)0.556 (−0.39 to 0.21)0.930 (−0.29 to 0.32) PLT (109/L)216.63 ± 70.07210.33 ± 53.33215.60 ± 53.760.0970.9080.683 (−24.27 to 36.87)0.947 (−29.54 to 31.60)0.733 (−35.84 to 25.30) D-Dimer (mg/L)1.43 ± 0.671.52 ± 0.801.56 ± 0.850.2010.8180.666 (−0.48 to 0.31)0.539 (−0.52 to 0.27)0.854 (−0.44 to 0.36)I, A vs B vs C; II, A vs B; III, A vs C; IV, B vs C Baseline characteristics of the patients according to study group I, A vs B vs C; II, A vs B; III, A vs C; IV, B vs C Outcome measures The primary outcome was the incidence of DVT confirmed by duplex ultrasonography on postoperative day 14. For the outcome indexes of the three groups, no VTE events occurred in group A, five cases of DVT occurred in group B (16.7%), and four cases of DVT occurred in group C (13.3%), there were no PE events in the three groups, and the incidence of VTE was significantly lower in group A than in groups B and C (Table 2). Table 2Experimental results and complicationsVariableGroup A (N = 30)Group B (N = 30)Group C (N = 30)Statisticsp-value (95% CI)IIIIIIIVKnee circumference (cm)42.27 ± 2.8344.68 ± 3.8344.15 ± 3.304.3120.0160.006 (−4.13 to −0.70)0.032 (−3.60 to −0.16)0.536 (−1.18 to 2.25)Intraoperative blood loss (mL)442.33 ± 138.69409.40 ± 140.48430.47 ± 145.880.4160.6610.371 (−39.80 to 105.66)0.746 (−60.86 to 84.60)0.566 (−93.80 to 51.66)DVT (%)0 (0)5 (16.7)4 (13.3)7.9210.0190.0200.0380.718PE (%)0 (0)0 (0)0 (0)-----Total bleeding complications (%)13 (43.3)10 (33.3)11 (37.8)0.6620.7180.4260.5980.787Subcutaneous ecchymosis (%)8 (26.7)5 (16.7)7 (23.3)0.9000.6380.3470.7660.519Wound bleeding (%)4 (13.3)2 (6.7)3 (10)0.7410.6900.3890.6880.640Gingival bleeding (%)1 (3.3)2 (6.7)0 (0)2.0690.3550.5540.3130.150Black stool (%)0 (0)1 (3.3)0 (0)2.0220.3640.313-0.313Hemoptysis (%)0 (0)0 (0)1 (3.3)2.0220.364-0.3130.313I, A vs B vs C; II, A vs B; III, A vs C; IV, B vs C Table 2Experimental results and complicationsVariableGroup A (N = 30)Group B (N = 30)Group C (N = 30)Statisticsp-value (95% CI)IIIIIIIVKnee circumference (cm)42.27 ± 2.8344.68 ± 3.8344.15 ± 3.304.3120.0160.006 (−4.13 to −0.70)0.032 (−3.60 to −0.16)0.536 (−1.18 to 2.25)Intraoperative blood loss (mL)442.33 ± 138.69409.40 ± 140.48430.47 ± 145.880.4160.6610.371 (−39.80 to 105.66)0.746 (−60.86 to 84.60)0.566 (−93.80 to 51.66)DVT (%)0 (0)5 (16.7)4 (13.3)7.9210.0190.0200.0380.718PE (%)0 (0)0 (0)0 (0)-----Total bleeding complications (%)13 (43.3)10 (33.3)11 (37.8)0.6620.7180.4260.5980.787Subcutaneous ecchymosis (%)8 (26.7)5 (16.7)7 (23.3)0.9000.6380.3470.7660.519Wound bleeding (%)4 (13.3)2 (6.7)3 (10)0.7410.6900.3890.6880.640Gingival bleeding (%)1 (3.3)2 (6.7)0 (0)2.0690.3550.5540.3130.150Black stool (%)0 (0)1 (3.3)0 (0)2.0220.3640.313-0.313Hemoptysis (%)0 (0)0 (0)1 (3.3)2.0220.364-0.3130.313I, A vs B vs C; II, A vs B; III, A vs C; IV, B vs C Experimental results and complications I, A vs B vs C; II, A vs B; III, A vs C; IV, B vs C For the secondary outcome measure of coagulation indexes, compared with the preoperative period, D-dimer, PT, APTT, and PLT increased in the three groups of patients after surgery, and FIB decreased compared with the previous period. Among them, the mean value of D-dimer in group A was significantly lower than that in groups B and C on the 14th day after operation: *P < 0.001 (95% CI −1.10 to −0.65) and #P < 0.001 (95% CI −0.69 to −0.23), and D-dimer in group C was significantly lower than that in group B: P < 0.001 (95% CI 0.19 to 0.64). PT and APTT in group A were higher than those in groups B and C: for PT, *P < 0.001 (95% CI −0.50 to 1.27) and #P < 0.001 (95% CI 0.23 to 1.01), and for APTT, *P = 0.012 (95% CI 0.60 to 4.70) and #P = 0.035 (95% CI 0.16 to 4.26), and there was no significant difference between the three groups in terms of FIB and PLT (Fig. 1).Fig. 1Coagulation index. *A < B. #A < C. & C < B Coagulation index. *A < B. #A < C. & C < B For the inflammatory indexes, we observed a significant increase in CRP, IL-6, ESR, WBC, and PCT in the postoperative period compared to the preoperative period. However, on the 14th postoperative day, CRP and PCT in group A were lower than those in groups B and C, while IL-6, ESR, and WBC did not show significant differences among the three groups: for CRP, *P < 0.001 (95% CI −4.96 to −1.57) and #P = 0.018 (95% CI −3.80 to −0.37), and for PCT, *P < 0.001 (95% CI −1.50 to −0.51) and #P = 0.018 (95% CI −1.44 to −0.44) (Fig. 2).Fig. 2Inflammatory indicators. *A < B. #A < C Inflammatory indicators. *A < B. #A < C For intraoperative blood loss, the difference between the three groups was not statistically significant. Postoperative blood loss complications occurred in 13 cases (43.3%) in group A, including 8 cases (26.7%) of subcutaneous petechiae, 4 cases (13.3%) of wound bleeding, and 1 case (3.3%) of gingival bleeding; in group B, there were 10 cases (33.3%), including 5 cases (16.7%) of subcutaneous petechiae, 2 cases (6.7%) of wound bleeding, 2 cases (6.7%) of gingival bleeding, and 1 case (3.3%) of dark stools (3.3%); Group C consisted of 11 cases (37.8%), including 7 cases (23.3%) of subcutaneous petechiae, 3 cases (10%) of wound bleeding, and 1 case (3.3%) of hemoptysis. Statistically analyzed, there was no significant difference in the incidence rate of hemorrhagic complications among the three groups. As for the knee circumference at 14 days after surgery, group A was significantly lower than groups B and C, and the difference was statistically significant (Table 2). Discussion The main finding of this randomized controlled trial is that rivaroxaban demonstrated superior prophylactic efficacy in preventing postoperative DVT in high-altitude residents undergoing TKA, with a lower DVT incidence and more favorable coagulation and inflammatory profiles than LMWH and fondaparinux, without an increased risk of bleeding. This highlights rivaroxaban as an effective and safe anticoagulant option for this unique high-risk population characterized by chronic hypoxia-induced hypercoagulability. KOA is a global disease and a major cause of pain, disability, and unemployment in humans [7]. Currently, TKA is considered the preferred approach for patients with advanced KOA. Although the procedure is effective in reducing pain, enhancing physical function, and improving overall quality of life, it is susceptible to postoperative deep vein thrombosis of the lower extremities, even leading to pulmonary embolism and acute myocardial infarction in some patients [8, 9], which poses a serious threat to patients’ lives. The formation of lower extremity deep vein thrombosis will lead to venous return obstruction, which is manifested as lower extremity swelling, pain, and dysfunction. Effective anticoagulation therapy can inhibit the progression of LEDVT, reduce the incidence of pulmonary embolism and death rate, and effectively control the recurrence rate [10]. According to the guidelines for prevention of venous thromboembolism in major orthopedic surgery and the American College of Chest Physicians guidelines for antithrombotic therapy [11, 12], LEDVT is one of the important postoperative complications after TKA and has a high incidence rate after TKA. Combined with the fact that people living at high altitude for a long period of time are characterized by long-term chronic hypoxia, which leads to secondary erythrocytosis, increased blood viscosity, slow blood flow, and other hemorheological changes, the risk of DVT is increased. Therefore, in order to improve the clinical outcomes of patients, it is crucial to analyze the safe and effective anticoagulant drugs for lower extremity DVT in hospitalized patients and to provide an effective reference basis for the prevention of lower extremity DVT in clinical departments. The results of the study showed that the postoperative treatment of KOA patients with rivaroxaban, low molecular heparin, and fondaparinux can effectively prevent lower extremity deep vein thrombosis. Low molecular heparin is a commonly used anticoagulant, which can inhibit the activity of coagulation factors and thrombin to achieve the purpose of antithrombotic therapy, but it needs to be injected by subcutaneous injection, which may cause injection pain and infection, resulting in poor patient compliance [13, 14]. Fondaparinux is a selective inhibitor of coagulation factor Xa mediated by antithrombin III. Fondaparinux binds to the oligosaccharide site in the structure of AT III through its short-chain portion, exposing the reactive center (arginine) of the anti-AT III reaction, which has a higher affinity for anticoagulant factor Xa, thus enhancing the original neutralizing activity of AT III against factor Xa by about 300 times, interrupting the coagulation waterfall chain, and inhibiting the formation of thrombus [15, 16]. Rivaroxaban is also one of the clinical drugs used in the treatment of peripheral vascular diseases, which prolongs APTT and PT in a dose-dependent manner by virtue of its highly selective and competitive inhibition of free and bound factor Xa and plasminogen activity [17], and is fundamentally different from low molecular heparin and fondaparinux in that it does not require the involvement of antithrombin III, directly antagonizes free and bound factor Xa, and catalyzes the inactivation of factor Xa, thereby blocking the formation of thrombi [18]. It can directly antagonize free and bound factor Xa and specifically catalyze the inactivation of factor Xa, thus blocking the common pathway of endogenous and exogenous activation pathways in the coagulation cascade, inhibiting thrombin molecules and preventing the formation of fibrin clot, and achieving the anticoagulant effect. As an oral drug capable of inhibiting the Xa factor, it has a rapid onset of action and good pharmacokinetic and pharmacodynamic properties and is effective in preventing deep vein thrombosis [19]. The main indications for rivaroxaban are the prevention of venous thrombosis and DVT after hip or knee arthroplasty, and contraindications include the presence of significant active bleeding, lesions with a significant risk of hemorrhage, hepatic disease with coagulation abnormalities and associated risk of hemorrhage, and a creatinine clearance of < 30 mL/min [20]. The results of the present study showed that rivaroxaban significantly reduced D-dimer and elevated D-dimer and D-hepatocyte levels in the treated patients, as compared with low molecular heparin sodium and fondaparinux. Rivaroxaban reduced D-dimer and elevated APTT and PT, while fondaparinux was superior to low molecular heparin sodium in its ability to reduce D-dimer. Therefore, the anticoagulant effect of oral rivaroxaban therapy in patients after total knee arthroplasty is superior to that of fondaparinux and low molecular heparin sodium. Studies have shown that surgery, braking, etc. can lead to slow venous blood flow [21–23]. Under normal circumstances, blood is in a laminar flow state; blood cells are mainly located in the central axis of the blood vessel, while near the wall of the blood vessel, there is mainly plasma. Blood cells flow into the edge of the flow, contacting the endothelial cells when the blood is slow, which makes it easy to develop pathologic thrombosis [24]. On the other hand, slow blood flow aggravates the hypoxic state of platelets to a certain extent, triggering cell damage, stimulating inflammatory reactions, and promoting thrombosis [25, 26]. Since the blood viscosity of patients in plateau areas is higher compared with normal people, the possibility of inflammatory reactions is greater. At the same time, inflammatory factors will damage the endothelial function of the patient’s blood vessels, enhancing platelet coagulation, so that the patient’s blood is in a state of hypercoagulability, which creates a vicious circle of aggravation of the disease. Therefore, the level of inflammatory factors can be used as one of the assessment indicators of the risk of thrombosis. The results of this study showed that rivaroxaban was effective in reducing postoperative CRP and PCT levels compared with sodium low molecular heparin and fondaparinux. Therefore, the use of rivaroxaban in the treatment of postoperative TKA is more effective in relieving patients’ postoperative inflammatory response. As for the problem of postoperative bleeding complications, the three groups did not show significant differences; however, for the improvement of postoperative swelling in patients, rivaroxaban had better performance. Conclusions In conclusion, the preventive effect of rivaroxaban on lower limb DVT after knee arthroplasty is better than that of low molecular heparin and fondaparinux; it can effectively control the patients’ blood rheology indexes, regulate coagulation indexes, and improve the vascular endothelial function; and it has a high degree of safety. Rivaroxaban, as a new oral anticoagulant, which is easy to administer, does not require routine monitoring, and can significantly improve patients’ medication compliance, has been rapidly popularized in the clinic. Therefore, the application of rivaroxaban has significant clinical advantages after knee arthroplasty at high altitude. It can effectively prevent the formation of lower extremity deep vein thrombosis and reduce the incidence of thrombosis, as well as alleviate the postoperative inflammatory reaction state and reduce the risk of postoperative infection faced by patients, while relieving knee swelling and providing patients with a better postoperative recovery experience. Supplementary Information Supplementary Material 1. Supplementary Material 1.